CRISPR Therapeutics AG

The U.S. Food and Drug Administration on Friday approved the country's first gene-editing treatment, Casgevy, for use in patients with sickle cell disease.The approval comes about a decade…

-Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel assigned Prescription Drug User…

<!-- Name:DistributionId Value:8788444 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8753889 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for…

-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical…

ZUG, Switzerland and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based…

ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based…

- More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001…

There are 537 million people around the world living with diabetes. And that number is growing. When people have Type 1 diabetes, the immune system attacks and destroys the beta cells in the…